Table 4.

Alcohol consumption and the risk for receptor-defined breast cancer among users and nonusers of menopausal hormone therapy

Control group
ERPR
ER+PR
ERPR+
ER+PR+
Unknown ER/PR
nnOR* (95% CI)nOR* (95% CI)nOR* (95% CI)nOR* (95% CI)nOR* (95% CI)
Never users of menopausal hormone therapy
    Recent alcohol use (g/d)
        No alcohol960991.0 (Ref)901.0 (Ref)281.0 (Ref)3671.0 (Ref)2501.0 (Ref)
        <5681871.2 (0.9-1.7)751.3 (0.9-1.8)100.4 (0.2-0.9)2441.0 (0.8-1.2)1891.2 (0.9-1.4)
        ≥5 to 10146171.1 (0.6-1.9)131.1 (0.6-2.0)10.2 (0.0-1.6)651.2 (0.9-1.7)371.0 (0.7-1.5)
        >1068121.8 (0.9-3.5)71.2 (0.5-2.8)0-261.1 (0.7-1.8)221.4 (0.9-2.4)
Ever users of menopausal hormone therapy
    Recent alcohol use (g/d)
        No alcohol171301.0 (Ref)231.0 (Ref)101.0 (Ref)921.0 (Ref)701.0 (Ref)
        <5237410.9 (0.6-1.6)351.2 (0.6-2.1)120.9 (0.3-2.1)1561.2 (0.9-1.7)860.8 (0.5-1.2)
        ≥5 to 1068141.1 (0.5-2.2)80.9 (0.4-2.2)20.5 (0.1-2.3)651.8 (1.2-2.8)301.0 (0.6-1.7)
        >103271.0 (0.4-2.6)71.5 (0.6-3.9)10.4 (0.0-3.2)241.4 (0.8-2.5)201.3 (0.7-2.4)
        Pinteraction0.780.970.700.300.57
  • * Adjusted for age, BMI (kg/m2), and age at first birth.

  • Estrogen alone (apart from oral estriol or local estrogen) or estrogen-progestin.